GeneDx Holdings (WGS) Other Operating Expenses (2022 - 2024)

GeneDx Holdings (WGS) has reported Other Operating Expenses for 3 consecutive years, with $2.6 million the latest figure, recorded in Q4 2024.

• On a quarterly basis, Other Operating Expenses fell 20.59% year-over-year to $2.6 million in Q4 2024; TTM through Sep 2025 was $2.6 million, a 285.59% increase from a year earlier, with the FY2023 full-year figure at -$2.0 million, up 69.0% from the prior year.
• Other Operating Expenses was $2.6 million for Q4 2024 at GeneDx Holdings, up from -$774000.0 in the prior quarter.
• Over five years, Other Operating Expenses peaked at $3.3 million in Q4 2023 and troughed at -$2.8 million in Q3 2023.
• A 3-year average of -$525400.0 and a median of -$924000.0 in 2024 frame the typical range for Other Operating Expenses.
• The widest YoY moves for Other Operating Expenses: up 306.38% in 2023, down 64.64% in 2023.
• Over 3 years, Other Operating Expenses stood at -$1.6 million in 2022, then surged by 306.38% to $3.3 million in 2023, then slipped by 20.59% to $2.6 million in 2024.
• The last three Other Operating Expenses figures came in at $2.6 million (Q4 2024), -$774000.0 (Q3 2024), and -$874000.0 (Q2 2024), per Business Quant data.